Search Results for: Clinical Trial Results Marks a
Articles
February 20, 2023
Kadimastem Submits IND Application for its Phase 2a Clinical Trial With AstroRx for the Treatment of ALS February 20, 2023
Kadimastem Ltd recently has submitted an Investigational New Drug (IND) application to the US FDA for an approval for a multi-site Phase 2a clinical trial to test its lead neurological….
February 13, 2023
Acumen Pharmaceuticals Completes Enrollment in Phase 1 Trial of First Monoclonal Antibody Developed to Selectively Target Toxic Aβ Oligomers in Patients With Early Alzheimer’s Disease February 13, 2023
Acumen Pharmaceuticals, Inc. recently announced the completion of enrollment in its Phase 1 INTERCEPT-AD trial of ACU193 in patients with early Alzheimer’s disease…..
December 13, 2022
Indaptus Therapeutics Announces Initiation of First-In-Human, Open Label, Dose Escalation & Expansion Multicenter Phase 1 Clinical Trial of Decoy20 in Patients With Advanced Solid Tumors December 13, 2022
Indaptus Therapeutics, Inc. recently announced the initiation of INDP-D101, its first-in-human, open-label, dose escalation and expansion, multicenter Phase 1 clinical...
May 2, 2022
Denali Therapeutics Announces Achievement of RIPK1 Milestone for Phase 2 Clinical Trial Initiation in ALS by Sanofi May 2, 2022
Denali Therapeutics Inc. recently announced its partner Sanofi has commenced dosing in a Phase 2 study, named HIMALAYA, of SAR443820...
April 28, 2022
Vaxxinity Completes Enrollment in Part B of UB-312 Phase 1 Clinical Trial for Parkinson’s Disease April 28, 2022
Vaxxinity, Inc. recently announced it has completed patient enrollment for Part B of its ongoing Phase 1 clinical trial of UB-312...
March 30, 2022
Acer Therapeutics Enrolls First Patient in its Phase 2a Clinical Trial for Treatment of Moderate to Severe Vasomotor Symptoms Associated With Menopause March 30, 2022
Acer Therapeutics Inc. recently announced the enrollment of the first patient in its Phase 2a randomized, double-blind, placebo-controlled, dose-ranging trial...
March 23, 2022
4D pharma Announces Positive Interim Results From Phase 1/2 Study March 23, 2022
4D pharma plc recently announced that in Part B of its signal finding study of MRx0518 in combination with MSD’s...
March 3, 2022
Fulcrum Therapeutics Announces Phase 3 Clinical Trial March 3, 2022
Fulcrum Therapeutics, Inc. recently announced its plans to initiate REACH, a Phase 3 clinical trial of losmapimod in people with...
February 1, 2022
ANAVEX2-73 (Blarcamesine) AVATAR Phase 3 Trial Met Primary & Secondary Efficacy Endpoints for the Treatment of Adult Patients With Rett Syndrome February 1, 2022
Anavex Life Sciences Corp. recently reported positive top-line results from the Phase 3 randomized, double-blind, placebo-controlled AVATAR trial of ANAVEX2-73 (blarcamesine) in adult female….
December 6, 2021
Ventyx Biosciences Announces First Patient Dosed in Phase 2 Clinical Trial of VTX002 for the Treatment of Moderate-to-Severe Ulcerative Colitis December 6, 2021
Ventyx Biosciences, Inc. recently announced the first patient has been dosed in a Phase 2 randomized, placebo-controlled trial of VTX002 for the treatment of moderate-to-severe ulcerative colitis (UC)…..
October 22, 2021
Athira Pharma Announces Completion of Enrollment in Phase 2 ACT-AD Trial Evaluating ATH-1017 for Mild-to-Moderate Alzheimer’s Disease October 22, 2021
Athira Pharma, Inc. recently announced it has completed enrollment in ACT-AD, a Phase 2 randomized, placebo-controlled study of ATH-1017 in...
October 5, 2021
Boehringer Ingelheim & OSE Immunotherapeutics Announce First Patient Dosed in Phase 1 Expansion Trial of SIRPα Antagonist Monoclonal Antibody BI 765063 in Combination With Anti-PD-1 Antibody Ezabenlimab, in Patients With Advanced Endometrium or Colorectal Tumors October 5, 2021
Boehringer Ingelheim and OSE Immunotherapeutics SA recently announced that the first patient has been dosed in the expansion phase of...
September 28, 2021
First Wave BioPharma Begins Patient Screening for Phase 2b Clinical Trial Evaluating Niclosamide in Patients With Ulcerative Proctitis & Ulcerative Proctosigmoiditis September 28, 2021
First Wave BioPharma, Inc. recently announced it has begun screening patients for enrollment in a Phase 2b clinical trial investigating...
April 14, 2021
Longeveron Announces Positive Results of Phase 1 Clinical Study of Lomecel-B Cell Therapy April 14, 2021
Longeveron Inc. recently announced the final results of its Phase 1 clinical study evaluating the safety and efficacy of intravenous...
April 8, 2021
New England Journal of Medicine Publishes Results of the PULSAR Phase 2 Trial of Sotatercept in Patients With Pulmonary Arterial Hypertension April 8, 2021
Acceleron Pharma Inc. recently announced the New England Journal of Medicine has published results of the PULSAR Phase 2 trial of...
December 9, 2020
Daré Bioscience Announces Positive Topline Results From Phase 3 Trial December 9, 2020
Daré Bioscience, Inc. recently announced positive topline results from the DARE-BVFREE Phase 3 randomized, double-blinded, placebo-controlled clinical trial evaluating DARE-BV1...
June 23, 2020
uniQure Announces First Two Patients Treated in Phase 1/2 Clinical Trial June 23, 2020
uniQure NV recently announced that the first two patients in the Phase 1/2 clinical trial of AMT-130 for the treatment...
February 20, 2020
Diasome Announces Positive Results from Phase 2 OPTI-1 Study February 20, 2020
Diasome Pharmaceuticals, Inc. recently announced positive results from its Phase 2 OPTI-1 study of injectable hepatocyte directed vesicle (HDV) added to...
October 23, 2019
Driving Improvements in Clinical Trial Results Sharing October 23, 2019
The world’s leading medical journals now require authors to disclose whether or not they’ll be sharing clinical trial results, a...
March 20, 2019